Shares of the company were up 2.3% in premarket trading following the results
PHOTO
Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study.
Shares of the company were up 2.3% in premarket trading following the results.
Moderna said it plans to engage with regulators on filing submissions for the vaccine candidate, mRNA-1010.
(Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
